B Cell-Activating Factor (BAFF) in Inflammatory Bowel Disease: BAFFling No Longer?

Striz, Ilja

doi:10.1007/s10620-016-4231-1

Cited by 6 publications

(6 citation statements)

References 10 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a bunch of biomarkers such as pANCA, ASCA, lactoferrin, S100A12, granulocyte–macrophage colony stimulating factor, soluble CD14, and lipopolysaccharide-binding protein have contributed to our understanding of IBD pathogenesis, none is of sufficient effective to warrant clinical development as predictive biomarkers 15 . This is the first study to compare the efficacy of faecal BAFF with faecal calprotectin and FOBT for discriminating IBS from IBD and assessment of intestinal inflammation in IBD after we identified BAFF as a novel biomarker in IBD 16 .…”

Section: Discussionmentioning

confidence: 99%

Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation

Wang

Xie

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Faecal calprotectin and faecal occult blood test (FOBT) were widely used in the diagnosis and assessment of intestinal inflammation in inflammatory bowel disease (IBD). Recently we identified an excellent new biomarker B cell-activating factor (BAFF) for IBD. Here in this study we compared the efficacy of faecal BAFF, calprotectin and FOBT to find the “best non-invasive marker”. Results showed that for discriminating IBD from IBS, BAFF ≥227.3 pg/ml yield 84% sensitivity, 100% specificity, 100% positive predictive value (PPV) and 64% negative predictive value (NPV) while calprotectin ≥50 µg/g yield 76% sensitivity, 93% specificity, 97% PPV and 53% NPV. FOBT yield 65% sensitivity, 93% specificity, 97% PPV and 43% NPV. Combining BAFF with calprotectin tests yield 94% sensitivity, 93% specificity, 98% PPV, 81% NPV. Faecal BAFF level showed the stronger correlation with endoscopic inflammatory score as compared to calprotectin not only in UC (correlation coefficient [r] = 0.69, p < 0.0001 vs. r = 0.58, p < 0.0001), but also in CD (r = 0.58, p < 0.0001 vs. r = 0.52, p = 0.0003). Our results indicating that faecal BAFF is a promising non-invasive biomarker in IBD differential diagnosis and monitoring of intestinal inflammation.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation

Wang

Xie

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…B-cell activating factor (BAFF), a member of the tumor necrosis factor (TNF) superfamily, recently emerged as a viable candidate for this role [ 15 ]. BAFF is predominantly produced by myeloid cells (monocytes, macrophages, dendritic cells and neutrophils), and its main role is regulation of mature B cell survival and differentiation into antibody-producing plasma cells [ 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

“…Overproduction of BAFF has been observed in various autoimmune diseases, most notably in systemic lupus erythematosus (SLE), where BAFF-inhibitor belimumab was approved for treatment [ 18 ]. Accordingly, accumulating data suggests that BAFF serum and fecal levels are elevated in patients with IBD [ 15 ]. Moreover, data obtained from colonic biopsies from IBD patients further supports involvement of BAFF in IBD pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease

et al. 2021

View full text Add to dashboard Cite

As early commencement of inflammatory bowel disease (IBD) treatment has been shown to substantially improve outcomes, it is of utmost importance to make a timely diagnosis of this disease. Despite undisputed sensitivity of fecal calprotectin, the most widely accepted IBD biomarker, in discriminating between irritable bowel syndrome (IBS) and IBD, as well as recognized role in monitoring disease activity and response to therapy, perhaps the biggest setback of calprotectin use in IBD is lack of specificity. Therefore, an additional biomarker in IBD is warranted. B-cell activating factor (BAFF), a member of the tumor necrosis factor (TNF) superfamily, recently emerged as a viable candidate for this role. So far, overproduction of BAFF has been observed in various autoimmune diseases, most notably in systemic lupus erythematosus, where BAFF-inhibitor belimumab was approved for treatment. As BAFF levels were also shown to correlate with indices of IBD, in this review we aimed to summarize the current evidence with respect to the role of BAFF in diagnosis and assessing the activity of IBD, as well as putative therapeutic implications that may arise from exploring of this relation.

show abstract

“…Therefore, it appears that in inflammatory conditions, cytokines cause non-hematopoietic cells to express BAFF, creating a local microenvironment that may facilitate the initiation of inflammation or reduce its persistence. 13,14 Several clinical experiments reported increased BAFF levels in particular tissues linked to the pathogenesis of inflammatory diseases, autoimmune diseases, and some malignancies, in addition to a significant amount of data from preclinical experiments. 30 The serum levels of BAFF appear to be increased in various autoimmune diseases, 31,32 such as rheumatoid arthritis, 33 Sjogren's syndrome, 34 systemic lupus erythematosus, 35 as well as IBD.…”

Section: Discussionmentioning

confidence: 99%

“…10 These evidences show a correlation between BAFF activity and clinical disease conditions and suggest BAFF as a potential clinical biomarker for IBD. 14 Various clinical diagnostic tests are available for H. pylori infection and related diseases. However, each diagnostic procedure has advantages, drawbacks, and limits.…”

Section: Introductionmentioning

confidence: 99%

Serum Calprotectin and B-cell activating factor are potential biomarkers for <i>Helicobacter pylori</i> infection

et al. 2023

View full text Add to dashboard Cite

Humans always mount a robust immune response to the bacterial infection caused by Helicobacter pylori, which causes various gastrointestinal tract infections. Calprotectin (CALP) and B-Cell Activating Factor (BAFF) are inflammatory biomarkers having a role in the gastrointestinal neutrophilic response to bacterial infection. The study was designed to assess serum CALP and BAFF as inflammatory biomarkers in H. pylori infection and peptic ulcer patients. The current study comprised 112 people, including 62 H. pylori-infected patients (34 men and 28 women) who were clinically diagnosed with H. pylori infection via testing positive for the H. pylori stool antigen test; they were compared to a control group of 50 healthy people (34 men and 16 women) who were age and gender-matched to H. pylori-infected patients. The serum level of CALP and BAFF were assayed using the ELISA technique. The biochemical parameters were statistically compared between patients and controls by unpaired Man-Whitney U t-test and Receiver Operating Characteristic (ROC) curve analysis. There was a significant elevation of serum CALP in H. pylori-infected patients [116.4(120.7), p=0.0132] in comparison to healthy controls [99.50(115.8)]. Similarly, there was a significant elevation of serum BAFF concentration in H. pylori-infected patients [485.7(367.1), p=0.0014] in comparison to healthy controls [444.5(513.0)]. The ROC curve analysis suggests serum CALP and BAFF as reasonable inflammatory biomarkers for H. pylori infection with statistically significant (p=0.0135, p=0.0015) area under the ROC curve of (0.6361, 0.6748), respectively. CALP and BAFF are potent inflammatory biomarkers involved in the development and etiology of H. pylori infection. Serum CALP and BAFF levels could be used as biomarkers for chronic inflammation induced by H. pylori. CALP and BAFF biomarkers can be combined to diagnose and predict the prognosis of H. pylori infection.

show abstract

B Cell-Activating Factor (BAFF) in Inflammatory Bowel Disease: BAFFling No Longer?

Cited by 6 publications

References 10 publications

Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation

Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation

Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease

Serum Calprotectin and B-cell activating factor are potential biomarkers for <i>Helicobacter pylori</i> infection

Contact Info

Product

Resources

About